Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
Recruiting
N/A
Interventional Study
Interstitial Lung Disease (ILD)
Suspected Interstitial Lung Disease
Fibrotic Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis (IPF)
Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Health Services Research
- Participants needed
- 92 (estimated)
- Sponsor
- Hospital de Granollers · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 18 years or older.
* Referral for suspected or undiagnosed interstitial lung disease (ILD).
* At least one of the following:
* A finding suggestive of ILD (such as reticulation, ground-glass opacities, traction bronchiectasis or honeycombing) not attributable to another…
Contacts
No contact information available.